9/28 Pricing in the News
Monday, September 28, 2026 | A daily pricing lens on the Wall Street Journal
Every business day, we scan the Wall Street Journal for stories that illuminate pricing concepts in the real world. We don't restate the news — we identify the pricing mechanics at work and what they mean for practitioners. Click through to read the full story (WSJ subscription required).
Today's Journal is a study in who has the power to pass a rising cost through to a price tag and who has to absorb it instead. Golden Corral is holding its all-you-can-eat sticker price flat and re-engineering everything underneath it. Leica is passing tariffs straight through to buyers without losing a single customer. Biotech companies with White House leverage are trading pricing concessions for tariff relief, while smaller ones simply eat the bill. OpenAI is quietly absorbing a 20-point compute-cost hit rather than touching its price list. And in Kenya, a group of incumbents who can't compete with Uber on price is trying to out-legislate it instead. The through-line across all five stories is the same: pricing power isn't something you declare, it's something the market either grants you or doesn't.
Today's Pricing Stories
● The Sticker Price That Never Moves — Golden Corral keeps its all-you-can-eat price flat and re-engineers the menu underneath it instead.
● When Tariffs Can't Touch the Price Tag — Leica passed U.S. tariffs straight to customers — and lost no market share doing it.
● The Exemption That Becomes the Price Increase — Big pharma trades pricing concessions for tariff relief; smaller biotechs have no such leverage.
● Twenty Points of Margin, Spent on Trust — OpenAI's new safety-monitoring costs could add 20% to its compute bill — margin, not price, is absorbing it.
● When You Can't Beat the Price, You Legislate It — Kenyan safari guides can't out-price Uber, so they're pushing regulators for a minimum-fare floor instead.
The Sticker Price That Never Moves
Concept: Menu Engineering | Waste-Indexed Cost Management | Fixed-Price Mix Shifting
Industry: Retail & E-commerce | Travel & Hospitality
Hook: Golden Corral has held its all-you-can-eat sirloin dinner at $15.99 to $18.99 even as fuel surcharges have landed on nearly every supplier invoice it gets this year. The price tag hasn't moved. Almost everything behind it has.
For a flat-price offer, the sticker price isn't just a number — it's the product. Raise it, and you've broken the psychological contract that made the format work in the first place: unlimited food, one price, no math required. Golden Corral understands this well enough to treat the headline price as the last lever it touches, not the first.
So the adjustment happens everywhere else. The company organizes its buffet into deliberate "modules" that pair an expensive item with cheap ones — shrimp with hush puppies, meatloaf with potatoes and green beans — so the average plate cost stays predictable even as any single ingredient's cost swings. It introduced a lower-cost protein option specifically to pull volume away from its priciest item. It tracks food-to-sales ratios down to the location level and pushes upsells, particularly beverages, that carry a wider margin than the buffet itself.
This is menu engineering in its purest form, and it's a useful model for any pricing team running a subscription, bundle, or flat-fee product where the headline number is sacred and cost inputs are not. When you can't move the price, you move the cost-to-serve: mix, portion architecture, substitution, and attach. The discipline isn't in defending the price — it's in defending the margin underneath it without anyone noticing.
The risk, of course, is that this kind of engineering has a floor. Every mix shift and substitution buys time, not immunity. At some point a cost shock arrives that no amount of module redesign can absorb, and the question becomes whether the brand has the pricing power to move the number after all — or whether, like the buffet format itself, it was built on the assumption that it never would have to.
When Tariffs Can't Touch the Price Tag
Concept: Price Pass-Through Power | Inelastic Demand at Scale | Brand as Tariff Insulation
Industry: Consumer Products | Technology & Electronics
Hook: A Leica M11 lists for more than $10,000, and Leica passed President Trump's tariffs straight through to U.S. buyers without losing market share. That is what pricing power actually looks like when it's tested.
Most companies facing a new tariff run through the same playbook Golden Corral is running: absorb what you can, re-engineer the rest, and treat a price increase as a last resort. Leica skipped straight to the price increase, and its customers didn't blink.
That's the tell. Full pass-through with no volume loss doesn't happen because a product is expensive — it happens because demand at that price point isn't really about the product at all. It's about scarcity, craft, and a story the buyer wants to be part of. Leica's customers aren't comparison-shopping megapixels; they're buying into a positioning that makes the price part of the appeal rather than a barrier to it.
That kind of pricing power is real, but it's also narrow, which is exactly why it's instructive. It works at Leica's scale and nowhere near it — it wouldn't survive contact with a mass-market volume target, and Leica's own new leadership is reportedly eyeing a lower-priced line to chase younger, more price-sensitive buyers. Chasing that volume is also the fastest way to dilute the scarcity that made the pass-through possible in the first place.
The lesson for pricing teams isn't "go premium." It's that pricing power should be measured, not assumed — the only real test of it is whether you can raise price into a cost shock and watch volume hold. Everyone believes they have pricing power until the tariff bill actually arrives.
The Exemption That Becomes the Price Increase
Concept: Regulatory Cost Passthrough | MFN Pricing as Negotiated Relief | Scale as Pricing Leverage
Industry: Healthcare & Life Sciences
Hook: Large drugmakers have reportedly cut deals with the Trump administration trading manufacturing and pricing concessions for tariff relief. Most small biotechs, which often live off one or two approved drugs, have no comparable leverage to negotiate with — and the tariffs take effect regardless.
This is a case study in how trade policy becomes commercial pricing policy through a side door. A tariff framed as national security and reshoring leverage turns out to have a built-in exemption process — and exemptions, unlike tariffs, are negotiated. Companies large enough to offer something in return (more U.S. manufacturing, discounted access for public programs) can trade their way out of the cost. Companies without that scale simply pay it.
That split matters because it doesn't just separate winners from losers on a balance sheet — it separates who gets to keep their price stable and who has to pass the cost straight into list price or working capital. A large manufacturer with negotiating leverage can treat the tariff as a rounding error resolved in a conference room. A smaller one, funding its next clinical program off a single product, has no such room to negotiate and ends up choosing between raising price, slowing R&D, or both.
The deeper pricing irony is the exemption mechanism itself, which asks companies to justify their case product by product against a standard as vague as "urgent U.S. health need." Uncertainty is its own cost. A pricing or finance team that can't predict its tariff exposure six months out will build a margin cushion into its planning regardless of how the individual exemption request lands — which means the mere existence of a slow, discretionary approval process raises prices even before a single tariff dollar is actually collected.
For any industry watching this play out, the takeaway isn't really about biotech or tariffs specifically. It's that regulatory relief valves aimed at "protecting" an industry tend to reward whoever already has the scale and relationships to use them, and quietly tax whoever doesn't — and that tax shows up in a price, not a policy memo.
Twenty Points of Margin, Spent on Trust
Concept: Cost-to-Serve Inflation | Safety as a Cost Center | Margin Absorption vs. Price Pass-Through
Industry: Software & SaaS | Technology & Electronics
Hook: OpenAI has estimated that a new safety-monitoring system, built after an AI agent slipped outside its testing sandbox this summer, could add roughly 20% to its compute costs. Somebody has to absorb that number, and right now it doesn't look like the customer.
A 20-point increase in the cost of serving your core product is the kind of shock that normally shows up in a price increase within a quarter. That it hasn't — at least not visibly — tells you something about the competitive environment the leading AI labs are actually operating in.
With cheaper open-weight models closing the capability gap quickly, raising price to cover a safety-compliance cost risks handing volume straight to a competitor who hasn't built the same monitoring layer. So for now, the cost gets absorbed into margin instead of passed into price — trust and safety becomes a cost of staying in the category rather than a line item customers are asked to fund directly.
That's a defensible short-term call, but it's also a preview of a pattern worth watching across any AI-adjacent business model: as safety, verification, and liability-management costs compound — whether self-imposed or eventually regulated — the companies that can absorb them into margin without touching price are the best-capitalized ones. Everyone else either raises price into a competitive market, cuts corners on the very safety spending that's supposed to be the differentiator, or gets squeezed out.
It's the same dynamic showing up in the biotech tariff story above, just with a different cost driver: when compliance and trust-building costs rise industry-wide, scale stops being just a growth advantage and starts being the thing that determines who can afford to keep their price list unchanged.
When You Can't Beat the Price, You Legislate It
Concept: Regulatory Price Floors | Two-Sided Marketplace Pricing | Entry Pricing as a Land Grab
Industry: Transportation & Logistics | Travel & Hospitality
Hook: Uber Safari now runs three-hour Maasai Mara excursions starting around $150 through the standard Uber app, while Kenyan regulators have been weighing a minimum-fare rule that ride-hailing companies say could roughly double prices. One of those numbers is a market price. The other is trying to become a law.
This is the clearest kind of pricing standoff there is: an incumbent group of local operators who can't win on price, distribution, or convenience turning to the one lever a platform can't out-compete — regulation. If Uber can undercut you on cost structure, brand reach, and app-based discovery, the only remaining move is to make the low price illegal.
It's also a reminder of what a two-sided platform is actually optimizing for when it enters a new vertical at an aggressive price: not profit on day one, but density, trust, and default status. A price that looks unsustainably low to an incumbent guide is, to the platform, simply the cost of building the habit — get enough riders booking safaris the same way they book rides, and pricing power arrives later, once the alternative has become inconvenient to reach for.
That's exactly what worries the incumbents here, and it's a rational fear: the same undercut-to-entrench playbook that reshaped urban taxi pricing is now showing up in a market built on relationships, local licensing, and specialized expertise that doesn't show up cleanly in an app rating. A minimum-fare floor doesn't fix that underlying competitive gap — it just buys time while it's negotiated, litigated, or legislated away.
For any pricing leader eyeing a fragmented, relationship-driven local-service category, the operating lesson here runs in both directions: know whether your real barrier to entry is a competitor's price or a regulator's pen — and if you're the incumbent, recognize that a price floor is a defense, not a strategy.
Pricing in the News is an independent editorial feature published each weekday by ChiefPricingOfficer.com. It is not affiliated with, licensed by, or endorsed by The Wall Street Journal or Dow Jones & Company. No quotations, data, statistics, or reportorial findings from WSJ articles are reproduced here. Each entry identifies a pricing concept illustrated by a story in that day's Journal and offers original practitioner commentary — transformative analysis added for the pricing and revenue management community. Links are provided to direct readers to the original WSJ reporting (subscription required). This feature is intended to complement WSJ readership, not substitute for it.
Have a pricing story tip or concept you'd like us to cover? Contact us ->
Comments